Christian Thirion, Dr.

Dr. Christian Thirion is the Managing Director and Founder of SIRION BIOTECH GmbH, a technology leader specializing in viral vector development and cell modeling for preclinical research and drug development.

Under Dr. Thirion's leadership, SIRION BIOTECH has become a prominent supplier to major European, US, and Japanese Drug and Biotech companies, offering viral vectors and cell models for target validation and assays.

The company's patented BAC technology enables the development of safer and more efficient viral vectors for experimental gene delivery and therapeutic applications, including cell-specific lentivirus vectors for targeted cell therapy.

SIRION BIOTECH's products include viral vectors for preclinical use, RNAiONE technology for cell models with knockdown rates close to 100%, and cell-based assays in primary human cells.

Dr. Thirion has established strategic partnerships with institutions like Helmholtz Zentrum München, TET Systems, Promega, and InSphero AG, focusing on oncology drug discovery, gene expression technology, and 3D cell models for cell-based assays.

The company is actively involved in preclinical development, with initiatives such as an Ad19a vaccination study in primates and research on radiation-sensitizing compounds in oncology.

Dr. Thirion's educational background includes studies in Biochemistry at Gene Center LMU Munich and Chemistry and Biochemistry at Ludwig-Maximilians-Universität München, where he obtained his Dr. and Diplomchemiker degrees.

His professional skills encompass biotech start-up management, financing, product development, preclinical development, grant coordination, and license and IP management.

Dr. Thirion is a member of various networks, including the Munich network and Bio Deutschland, with a goal of expanding the global business activities of SIRION BIOTECH and advancing the development of predictive in vitro cell models.